Investigation on how alemtuzumab acts in patients with relapsing remit
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential
What was tested
Treatment tested
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
Absolute and relative change from baseline of the following cell-counts in the peripheral blood:
Other measures (1)
1. Absolute and relative change from baseline in cell-counts in the CSF. The same cell-types as indicated for the primary endpoints will be evaluated.
Blood or spinal fluid markers
Papers
Loading reviews and guidelines…
Related trials
- The HIt HArd and hiT Early in Multiple Sclerosis Trial
Phase 2 · Recruiting
Still running
- Effects of CLADribine tablets on the Immune Synapse, in Relapsing Mult
Phase 4 · Not yet recruiting
Still running
- No Evidence Of Disease Activity After Autologous Haematopoietic Stem C
Phase 2 · Stopped early
Stopped
- Cladribine Tablets Level of Response Predictors in Clinical Practice (
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No results found
- A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY
Running, not recruiting
Still running
History
- In scope changed from true to false
Started
Oct 2014
Assembled by software from public sources.